July 4, 2022
EPS Holdings, Inc.
EP-Sogo Co., Ltd.
EPS International Holdings Co., Ltd.
News Release

EP-SOGO and EPS International Announce Reorganization of SMO Taiwan
EPS International Holdings Co., Ltd. (“EPS International” hereafter) and EP-Sogo Co., Ltd. (“EPSOGO” hereafter), both of which are wholly owned subsidiaries of EPS Holdings, Inc., announced
that EPS International and EP-SOGO have agreed to transfer all shares of Total Trial Management
Consulting Co., Ltd. ("TTMC" hereafter), a wholly owned subsidiary of EPS International andoperating a SMO business in Taiwan, to EP-SOGO, one of largest SMOs in Japan.
1. Purpose of the Reorganization
Last year, the EPS Group celebrated its 30th anniversary and conducted a management buyout(MBO), moving toward "the New EPS". The reorganization of the domestic CRO business wascompleted on schedule as of 1st July 2022, and this reorganization is related to the overseas businessfollowing the domestic business.
TTMC has been providing localized services as an SMO in Taiwan for more than 20 years since its
establishment. Until now, TTMC has been part of our overseas business belonging to the Global
Research segment and operated as a subsidiary of EPS International.
EP-SOGO supports clinical trials and post-marketing clinical trials conducted by medical
institutions for pharmaceuticals, medical devices, and regenerative medicine products as theindustry's leading SMO in Japan. At this time, EP-SOGO has decided to acquire TTMC as a direct
subsidiary in order to further develop TTMC capabilities by sharing the experience and know-howof EP-SOGO and creating synergistic effects.
In the domestic SMO business, for example, the business environment surrounding SMOs has beenchanging dramatically, as DCT (Decentralized Clinical Trials) have begun to spread and the needfor remote access to medical records is rapidly increasing due to the COVID-19 pandemic. Inresponse to these changes in the environment, EP-SOGO has been actively creating solutions, suchas the development of the next-generation Remote SDV*1 system "SYNOV-R". In Taiwan, where
the healthcare system and environment are much closer to those of Japan than in other countries,
EP-SOGO is expected to be able to utilize its expertise in the SMO business.

Overview of Transferred Company
Total Trial Management Consulting Co. Ltd.

Name（全面顧問股份有限公司）

Address

8F, No.560, Sec 4 , Zhongxiao E. Road,
Xinyi Dist. Taipei City 110, Taiwan (R.O.C.)

Representative Director

Takihiro HIRASAWA

Number of Employees*

25

CapitalTWD 1,500,000*As of July 1, 2022

2. Schedule
After discussing the details of this share transfer, EP-SOGO and EPS International will conclude ashare transfer agreement, and the shares are scheduled to be transferred in early August 2022.
About EPS group
Since its establishment in 1991 as one of pioneering CROs, EPS Group has been a Healthcare Solution
Provider to pharmaceutical companies, medical device manufacturers, hospitals and clinics, andacademia with various solutions from development to marketing, sales, consultation covering Asia
centered in China and new values created in big data & AI, regenerative medicine, etc. The strength ofEPS Group lies in the fact that it has the greatest presence in Japan. In Asia, the company has multiple
overseas offices and has focused particularly on solidifying its sites in the respective Asian countries,providing clinical development support services as well as SMO services.
*1. Remote SDV : A method of directly accessing source documents such as medical records and worksheets from outside
a medical institution (remote location) and verifying the submitted data against the records on the source
documents.

Contact:
EPS Holdings, Inc.
Corporate Communications Office
Email: pr@eps.co.jp